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ABSTRACT 
BACKGROUND AND OBJECTIVE 
         Ulcers are a cause of morbid illness prolonging the hospital stay of 
patients for want of utmost care in order to avoid amputations. Various  
advanced treatment modalities are being available these days to reduce 
the morbidity and quicken the process of healing 
    One such readily available product is the Human Recombinant 
Epidermal Growth Factor which has proven efficacy in increasing the 
healing rate.  This study is aimed at comparing the efficacy of rhEGF 
(available in the brand name REGEN D 150) to normal saline dressings 
in improving the healing rate of large ulcers . 
METHODS 
 Between March 2016 and September 2016, 104 patients with 
ulcers who got admitted to Institute of General Surgery, Rajiv Gandhi 
Government General Hospital, Chennai were recruited to the study by 
randomising them to test and control groups. The study ended with 100 
patients , 50 in each group and both the systems were compared. The 
effects of rhEGF on wound healing were analysed and compared to that 
of the conventional normal saline dressing. 
 
RESULTS 
 The study group dressed with rhEGF showed a significant 
reduction in size of the ulcers irrespective of other comorbidities or sites 
of ulcer. The healing rate was calculated as percentage reduction in size 
per week and the significance was analysed. Further analysis was done on 
the infectivity rate of ulcers in each group and found that rhEGF 
significantly prevents ulcers from micro organism colonisation. 
INTERPRETATION AND CONCLUSION 
The efficacy of rhEGF in ulcer healing as analysed in many studies 
was found to be higher than the usual conventional normal saline dressing 
and this effect was statistically significant. Large ulcers treated with 
rhEGF showed an increased healing rate and ulcer was made ready for 
skin grafting sooner than usual thus avoiding unnecessary amputations. 
KEY WORDS 
ulcers, wound healing, growth factors, rhEGF, normal saline, 
wound dressing, diabetes, infection, antibiotics 
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INTRODUCTION 
           Skin ulcers occur more commonly in individuals and are being 
treated with different modalities on a day to day basis. And the same 
progressing to chronicity or towards complete healing is influenced by 
many number of internal and external factors. 
           Healing of ulcers can be impaired due to venous disease, arterial 
disease, and neuropathy. “Less common causes are metabolic disorders, 
haematological disorders, and infective diseases. Ulcer management 
involves a comprehensive care plan with consideration of all factors 
contributing to the ulcer and the patient”. “No single discipline can meet 
all the needs of a patient with an ulcer”. 
“Chronic ulcers that are resistant to healing because of the growth 
of multidrug resistant organisms and microvascular complications exhibit 
decrease in both angiogenic response and the production of growth 
factors”. Some of these factors can be generated by recombinant  DNA 
technology and these in turn when used on ulcers are known to accelerate 
wound healing. One such factor is the recombinant Human Epidermal 
Growth Factor which helps in the stimulation of cell growth resulting in 
faster wound healing. 
         “The recombinant human EGF is a single chain polypeptide with 
54 amino acids. It is identical to that of human natural EGF composed of 
53 amino acids”.  
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AIM OF STUDY 
 
• TO COMPARE THE EFFICACY OF RECOMBINANT HUMAN 
EPIDERMAL GROWTH FACTOR WITH THAT OF NORMAL 
SALINE DRESSING IN ULCER HEALING. 
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REVIEW OF LITERATURE 
“From the era of living in caves, men have been tending to their  
wounds. Wound care has evolved from incantations, potions, and local 
applications to a systematic text of wound care and surgery from 
Hippocrates and Celcius”. 
         “The Middle Ages regressed back to charms and potions and this 
continued till the time of great wars when wound care emerged again”. 
“In history, this was followed by the realisation of the necessity of 
hygiene and the halting of bleeding, where wound dressing and surgical 
skills developed. Eventually the germ theory of disease also assisted in 
improving wound care’. 
         The first advances in wound care began in 19th century with the 
work of Ignaz Philip Semmelweis, a Hungerian obstetrician who 
developed sterile surgical procedures and Louis Pasteur, a French scientist 
known as the Father of Microbiology for his germ theory. 
WOUND DRESSING: PAST TO PRESENT 
“With advancements in materials and tissue science, the field of 
wound dressings has evolved considerably. The ability to bolster wound 
re-epithelialization has been improved. The advent of numerous synthetic 
products in the field of wound care have significantly accelerated the 
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process of natural wound healing”. Semmelweis’s work was furthered by 
an English surgeon, Joseph Lister, who began treating his surgical gauze 
with carbolic acid, known today as phenol, and subsequently dropped his 
surgical team’s mortality rate by 45%. Building on the success of Lister’s 
pretreated surgical gauze, Robert Wood Johnson co-founder of Johnson & 
Johnson began producing gauze and wound dressing treated with Iodine. 
These innovations in wound-site dressings marked the first major 
steps forward in the field since the advances of the Egyptians and Greeks, 
centuries earlier. 
The next advances would arise from the development of polymer 
synthetics for wound dressings and the “rediscovery” of moist wound-site 
care protocols. 
THE PROCESS OF WOUND HEALING 
“The process by which tissue repair takes place is termed wound 
healing and is comprised of a continuous sequence of inflammation and 
repair, in which epithelial, endothelial, inflammatory cells, platelets and 
fibroblasts briefly come together outside their normal domains, interact to 
restore a semblance of their usual discipline and having done so resume 
their normal function”. 
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“The process of wound repair differs little from one kind of tissue 
to another and is generally independent of the form of injury. Although 
the different elements of the wound healing process occur in a continuous, 
integrated manner, it is convenient to divide the overall process into three 
overlapping phases and several natural components for descriptive 
purposes”. 
Inflammatory Phase:(Day 0-5) 
Coagulation 
“The healing response is initiated at the moment of injury. Surgical 
or traumatic wounds disrupt the tissue architecture and cause 
haemorrhage. Initially, blood fills the wound defect and exposure of this 
blood to collagen in the wound leads to platelet degranulation and 
activation of Hageman factor. This in turn sets into motion a number of 
biological amplification systems including the complement kinin and 
clotting cascades and plasmin generation. These serve to amplify the 
original injury signal and lead not only to clot formation, which unites the 
wound edges, but also to the accumulation of a number of mitogens and 
chemoattractants at the site of wounding”. 
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Inflammation 
“Production of both kinins and prostaglandins leads to 
vasodilatation and increased small vessel permeability in the region of the 
wound . This results in oedema in the area of the injury and is responsible 
for the pain and swelling which occurs early after injury. Within 6 h, 
circulating immune cells start to appear in the wound. Polymorphonuclear 
leucocytes (PMN) are the first blood leucocytes to enter the wound site. 
They initially appear in the wound shortly after injury and subsequently 
their numbers increase steadily, peaking at 24-48 h . Their main function 
appears to be phagocytosis of the bacteria which have been introduced 
into the wound during injury. The presence of PMN in the wound 
following injury does not appear to be essential in order for normal 
wound healing to take place , with healing proceeding normally in their 
absence provided that bacterial contamination has not occurred. In the 
absence of infection, PMN have a relatively short life span in the wound 
and their numbers decrease rapidly after the third day” . 
“The next cellular, immune element to enter the wound are 
macrophages. These cells are derived from circulating monocytes by a 
combination of migration and chemotaxis. They first appear within 48-96 
h post-injury and reach a peak around the third day post-injury. These 
macrophages have a much longer life span than the PMN and persist in 
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the wound until healing is complete. Their appearance is followed 
somewhat later by T lymphocytes, which appear in significant numbers 
around the fifth day post-injury, with peak numbers occurring about the 
seventh day after injury. In contrast to PMN, the presence and activation 
of both macrophages and lymphocytes in the wound is critical to the 
progress of the normal healing process”. 
“Macrophages just like neutrophils phagocytose and digest 
pathological organisms and tissue debris. In addition, macrophages 
release a plethora of biologically active substances. Many of these 
substances facilitate the recruitment of additional inflammatory cells and 
aid the macrophage in tissue decontamination and debridement; in 
addition growth factors and other substances are also released which are 
necessary for the initiation and propagation of granulation tissue 
formation. These intercellular transmitters are known collectively as 
cytokines”. 
Proliferative Phase: (Day 3-14) 
“In the absence of significant infection or contamination the 
inflammatory phase is short, and after the wound has been successfully 
cleared of devitalized and unwanted material it gives way to the 
proliferative phase of healing. The proliferative phase is characterized by 
the formation of granulation tissue in the wound”. 
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Fibroplasia 
 “Granulation tissue consists of a combination of cellular elements, 
including fibroblasts and inflammatory cells, along with new capillaries 
embedded in a loose extra cellular matrix of collagen, fibronectin and 
hyaluronic acid. Fibroblasts first appear in significant numbers in the 
wound on the third day post-injury and achieve peak numbers around the 
seventh day. This rapid expansion in the fibroblast population at the 
wound site occurs via a combination of proliferation and migration. 
Fibroblasts are derived from local mesenchymal cells, particularly those 
associated with blood vessel adventitia, which are induced to proliferate 
and attracted into the wound by a combination of cytokines produced 
initially by platelets and subsequently by macrophages and lymphocytes. 
Fibroblasts are the primary synthetic element in the repair process and are 
responsible for production of the majority of structural proteins used 
during tissue reconstruction. In particular, fibroblasts produce large 
quantities of collagen, a family of triple-chain glycoproteins, which form 
the main constituent of the extracellular wound matrix and which are 
ultimately responsible for imparting tensile strength to the scar. Collagen 
is first detected in the wound around the third day post-injury, and 
thereafter the levels increase rapidly for approximately 3 weeks. It then 
continues to accumulate at a more gradual pace for up to 3 months post 
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wounding. The collagen is initially deposited in a seemingly haphazard 
fashion and these individual collagen fibrils are subsequently reorganised, 
by cross-linking, into regularly aligned bundles oriented along the lines of 
stress in the healing wound. Fibroblasts are also responsible for the 
production of other matrix constituents including fibronectin, hyaluronic 
acid and the glycosaminoglycans. The process of fibroblast proliferation 
and synthetic activity is known as fibroplasias”. 
Revasculariation 
“Revascularization of the wound proceeds in parallel with 
fibroplasia. Capillary buds sprout from blood vessels adjacent to the 
wound and extend into the wound space. On the second day post-injury, 
endothelial cells from the side of the venule closest to the wound begin to 
migrate in response to angiogenic stimuli. These capillary sprouts 
eventually branch at their tips and join to form capillary loops, through 
which blood begins to flow. New sprouts then extend from these loops to 
form a capillary plexus. The soluble factors responsible for angiogenesis 
remain incompletely defined. It appears that angiogenesis occurs by a 
combination of proliferation and migration. Putative mediators for 
endothelial cell growth and chemotaxis include cytokines produced by 
platelets, macrophages and lymphocytes in the wound, low oxygen 
tension, lactic acid and biogenic amines. Of the potential cytokine 
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mediators of neovascularization basic fibroblast growth factor (bFGF), 
acidic FGF (aFGF), transforming growth factors-a and b (TGF-a and -b) 
and epidermal growth factor (EGF) have all been shown to be potent 
stimuli for new vessel formation. FGF, in particular, has been shown to be 
a potent inducer of in vivo neovascularisation”. 
Re-epithelialization 
“While these events are proceeding deep in the wound, restoration 
of epithelial integrity is taking place at the wound surface. Re-
epithelialization of the wound begins within a couple of hours of the 
injury. Epithelial cells, arising from either the wound margins or residual 
dermal epithelial appendages within the wound bed, begin to migrate 
under the scab and over the underlying viable connective tissue. The 
epidermis immediately adjacent to the wound edge begins thickening 
within 24 h after injury. Marginal basal cells at the edge of the wound 
loose their firm attachment to the underlying dermis, enlarge and begin to 
migrate across the surface of the provisional matrix filling the wound. 
Fixed basal cells in a zone near the cut edge undergo a series of rapid 
mitotic divisions, and these cells appear to migrate by moving over one 
another in a leapfrog fashion until the defect is covered. Once the defect is 
bridged, the migrating epithelial cells loose their flattened appearance, 
become more columnar in shape and increase in mitotic activity. Layering 
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of the epithelium is re-established and the surface layer eventually 
keratinized. Reepithelialization is complete in less than 48 h in the case of 
approximated incised wounds, but may take substantially longer in the 
case of larger wounds where there is a significant tissue defect. If only the 
epithelium is damaged, such as occurs in split thickness skin graft donor 
sites, then repair consists primarily of re-epithelization with minimal or 
absent fibroplasia and granulation tissue formation. The stimuli for re-
epithelization remain incompletely determined, but it appears that the 
process is mediated by a combination of loss of contact inhibition, 
exposure of constituents of the extracellular matrix, particularly 
fibronectin, and by cytokines produced by immune mononuclear cells. 
EGF, TGF-b, bFGF, platelet-derived growth factor (PDGF) and insulin 
like growth factor-l (IGF-l) in particular, have been shown to promote 
epithelialisation”. 
Maturation Phase: (Day 7 to I Year) 
“Almost as soon as the extracellular matrix is laid down, its 
reorganization begins. Initially, the extracellular matrix is rich in 
fibronectin, which forms a provisional fibre network. This serves not only 
as a substratum for migration and ingrowth of cells, but also as a template 
for collagen deposition by fibroblasts. There are also significant quantities 
of hyaluronic acid and large molecular weight proteoglycans present, 
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which contribute to the gel-like consistency of the extracellular matrix 
and aid cellular infiltration. Collagen rapidly becomes the predominant 
constituent of the matrix. The initially randomly distributed collagen 
fibres become cross-linked and aggregated into fibrillar bundles, which 
gradually provide the healing tissue with increasing stiffness and tensile 
strength. After a 5-day lag period, which corresponds to early granulation 
tissue formation and a matrix largely composed of fibronectin and 
hyaluronic acid, there is a rapid increase in wound breaking strength due 
to collagen fibrogenesis. The subsequent rate of gain in wound tensile 
strength is slow, with the wound having gained only 20% of its final 
strength after 3 weeks. The final strength of the wound remains less than 
that of uninjured skin, with the maximum breaking strength of the scar 
reaching only 70% of that of the intact skin”. 
“This gradual gain in tensile strength is due not only to continuing 
collagen deposition, but also to collagen remodelling, with formation of 
larger collagen bundles and alteration of intermolecular crosslinking. 
Collagen remodelling during scar formation is dependent on both 
continued collagen synthesis and collagen catabolism. The degradation of 
wound collagen is controlled by a variety of collagenase enzymes, and the 
net increase in wound collagen is determined by the balance of these 
opposing mechanisms. The high rate of collagen synthesis within the 
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wound returns to normal tissue levels by 6-12 months, while active 
remodelling of the scar continues for up to 1 year after injury and indeed 
appears to continue at a very slow rate for life”. 
 “As remodelling progresses, there is a gradual reduction in the 
cellularity and vascularity of the reparative tissue which results in the 
formation of a relatively avascular and acellular collagen scar. Grossly 
this can be observed as a reduction in erythema associated with the earlier 
scar and some reduction in the scar volume, resulting in a pale thin scar. 
This is normally a desirable feature of healing; however, in some cases 
shrinkage of the scar may give rise to an undesirable reduction in skin 
mobility resulting in contracture”. 
Wound contraction 
“It involves the inward movement of the wound edge, is a further 
important element in the healing process and should be distinguished 
from contracture. Sharply incised wounds without significant tissue loss, 
approximated early after injury, heal rapidly without the need for 
significant reduction in the wound volume. Such wounds are described as 
having healed by primary intention. Large wounds, however, particularly 
those associated with significant tissue loss, heal by secondary intention, 
with granulation tissue gradually filling the defect and epithelization 
proceeding slowly from the wound edges. Contraction of the wound 
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edges can lead to a significant reduction in the quantity of granulation 
tissue required to fill the wound defect and a reduction in the area 
requiring reepithelization, with a consequent reduction in scar volume. 
Contraction is only undesirable where it leads to unacceptable tissue 
distortion and an unsatisfactory cosmetic result. Although contraction 
normally accounts for a larger part of overall wound closure in loose 
skinned animals, it still accounts for a significant proportion of the 
healing process in man, particularly in areas where the skin is not tightly 
bound down to underlying structures, such as on the back, neck and 
forearms. Initially following injury, where the wound edges are not 
approximated, there is a slight retraction of the wound edges due to the 
release of normal elastic tension in the skin, with a resultant increase in 
wound volume. The wound area starts to decrease rapidly from the third 
day onwards. While this is due in part to reepithelization, the main reason 
is an inward movement of the uninjured skin edges. Wound contraction 
usually begins around the fifth day postwounding and is complete by 12-
15 days after wounding. Fibroblasts within the wound appear to be 
responsible for providing the force for this contractile activity. It was 
initially felt that specialized fibroblasts called myofibroblasts provided the 
motive force for wound contraction via a muscle like cell contraction. 
More recent studies reveal that wound contraction occurs as a result of an 
interaction between fibroblast locomotion and collagen reorganisation. 
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The contraction is thought to be mediated via the attachment of collagen 
fibrils to cell surface receptors, with the resulting tractional forces 
generated by cell motility bringing the attached collagen fibrils closer 
together and eventually compacting them”. 
 “The regulation of wound contraction remains poorly defined. 
Information regarding the effects of specific cytokines on contraction is 
limited and often conflicting. TGF-b has been found to promote 
contraction even in the absence of serum”  
Scar Formation 
“As mentioned previously, the process of wound healing is 
essentially similar in all tissues and is relatively independent of the mode 
of injury; however, slight variation in the relative contribution of the 
different elements to the overall result may occur. The final product of the 
healing process is a scar. This relatively avascular and acellular mass of 
collagen serves to restore tissue continuity, strength and function. Delays 
in the healing process cause the prolonged presence of wounds, while 
abnormalities of the healing process may lead to abnormal scar formation. 
Successful completion of wound healing may not always yield the desired 
clinical result, particularly where the final cosmetic appearance of the scar 
is of primary importance”. 
      
 
WOUND HEALING
GROWTH FACTORS
“The understanding of concepts of growth factors 
over the decade has brought new field of interest in their usage in chronic 
ulcers”. Various studies conducted in vitro 
efficacy in cell proliferation and angiogenesis and wound contraction.
“Recombinant technology made it possible to acquire adequate 
quantity of growth factors for human trials. Many such trials
factor use in wound 
topical treatment of chronic and large wounds 
amputations to a certain extent
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“Growth factors are proteins secreted from many tissues in the 
body and exert varied effects on cell function. Growth factors stimulate or 
inhibit progression through the cell cycle that control cell viability or 
death, or that act principally to regulate cell differentiation”. 
Their modes of action include  
• autocrine, 
• paracrine,  
• juxtacrine,  
• intracrine modes.  
Autocrine actions are mediated by a growth factor on its cell of 
origin after its secretion into the extra cellular environment”. “Paracrine 
actions occur when a growth factor that is secreted by one cell has an 
effect on adjacent cells.  
Juxtacrine is similar to paracrine except that the growth factor is 
bound to the cell membrane or extra cellular matrix. 
Intracrine actions occur inside the cell of origin. The effects of 
growth factors are mediated by activation of specific receptors which are 
transmembrane proteins”. 
 
      
 
Table 1 shows various growth 
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TISSUE MANAGEMENT/WOUND BED PREPARATION 
A. DEBRIDEMENT 
“Debridement of necrotic tissue is an integral component in the 
treatment of chronic wounds since they will not heal in the presence of 
unviable tissue, debris, or critical colonization. Undermined tissues or 
closed wound spaces would otherwise harbour bacterial growth. 
Debridement serves various functions: removal of necrotic tissue and 
callus; reduction of pressure; evaluation of the wound bed; evaluation of 
tracking and tunnelling; and reduction of bacterial burden. Debridement 
facilitates drainage and stimulates healing. However, debridement may be 
contraindicated in arterial ulcers. Additionally except in avascular cases, 
adequate debridement  must always precede the application of topical 
wound healing agents, dressings, or wound closure procedures. Of the 
five types of debridement (surgical, enzymatic, autolytic, mechanical, 
biological), only surgical debridement has been proven to be efficacious 
in clinical trials”.  
 
(i) SURGICAL DEBRIDEMENT 
“Surgical Debridement is the cornerstone of management of 
necrotising fasciitis and abscesses. Thorough sharp debridement of all 
nonviable soft tissue and bone from the open wound is accomplished with 
a scalpel, curettes, and curved scissors. Excision of necrotic tissue extends 
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as deeply and proximally as necessary until healthy, bleeding soft tissue 
and bone are encountered. Any callus tissue surrounding the ulcer must 
also be removed. The main purpose of surgical debridement is to turn an 
infected or necrotic soft tissue into an acute healing wound. Ulcers 
associated with a deep abscess requires hospital admission and immediate 
incision and drainage. Joined resection or partial amputation of the foot is 
necessary if osteomyelitis, joint infection, or gangrene is present. Necrotic 
tissue removed on a regular basis can expedite the rate at which a wound 
heals and has been shown to increase the popularity of attaining full 
secondary closure. Less frequent surgical debridement can reduce the rate 
at which a wound is healing and secondarily increase the risk of infection. 
Surgical debridement is repeated as often as needed if new necrotic tissue 
continues to form. Frequent debridement, referred to as maintenance 
debridement, is commonly required”. 
(ii) ENZYMATIC DEBRIDEMENT 
“A highly selective method, enzymatic debridement consists of the 
application of exogenous proteolytic enzymes specifically manufactured 
for wound debridement. Various enzymes have been developed, including 
bacteria collagenase, plant derived papain / urea, fibrinolysin / DNAse, 
trypsin, streptokinase - streptodornase combination; only the first three 
products are widely available commercially. Collagenases are enzymes 
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that are isolated from Clostridium histolyticum. These specify high 
specificity for the major collagen types (I and II), but they are not active 
against keratin, fat, or fibrin. Papain, obtained from the papaya plant is 
effective in the breakdown of fibrinous material and necrotic tissue. When 
combined with urea, it denatures nonviable protein matter. The enzymatic 
compounds are inactivated by hydrogen peroxide, alcohol and heavy 
metals including silver, lead and mercury. One study found that wounds 
treated with papain-urea developed granulation tissue faster than those 
treated with collagenase”. 
(iii)  MECHANICAL DEBRIDEMENT 
“A nonselective, physical method of removing necrotic tissue, 
mechanical debridement may include wet-to-dry dressings and high-
pressure irrigation or pulsed lavage and hydrotherapy. Wet-to-dry is one 
of the most commonly used and overused methods of debridement in 
acute care settings. Hydrotherapy in the form of whirlpool may remove 
surface skin, bacteria, wound exudates, and debris. There may be 
justification in the early stages of the wound for the use of this technique, 
but it is detrimental to friable granulation tissue”.  
B. BIOLOGICAL (MAGGOT) THERAPY 
“Larval therapy utilizes the sterile form of the Lucilia sericata 
blowfly for the debridement of necrotic and infected wounds. Maggots 
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secrete a powerful proteolytic enzyme that liquefies necrotic tissue. It has 
been noted that wound odour and bacterial count, including methicillin-
resistant Staphylococcus Aureus, diminish significantly with larval 
therapy. Larval therapy seems to be beneficial, but there is paucity of 
controlled studies to support its routine use in the diabetic foot wound”. 
C. MOISTURE BALANCE 
“One of the major breakthroughs in wound management over the 
past  50 years was the demonstration that moisture accelerates re-
epithelialization in a wound. Tissue moisture balance is a term used to 
convey the importance of keeping wounds moist and free of excess fluids. 
A moist wound environment promotes granulation and autolytic 
processes. Effective management of chronic wound fluids is an essential 
part of wound bed preparation; it also helps in addressing the issues of 
cellular dysfunction and biochemical imbalance”. 
D. DRESSINGS 
“Wound dressings can be categorized as passive, active or 
interactive. Passive dressings primarily provide a protective function. 
Active and interactive dressings and therapies are capable of modifying a 
wound’s physiology by stimulating cellular activity and growth factor 
release. An example is oxidized regenerated cellulose / collagen 
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(Promogran, Johnson & Johnson Inc., New Brunswick, NJ). Composed of 
collagen and oxidised regenerated cellulose, this bioabsorbable matrix 
decreases tissue destruction and prevents growth factor degradation. 
Recently silver has been added to this product (Prisma, Johnson & 
Johnson Inc., New Brunswick, NJ)  to also provide an effective 
antibacterial buffer. Although these products are commonly used in 
clinical practice, they have not yet been conclusively shown to expedite 
wound healing”.  
 
Table 2 TIME principles of wound bed preparation  
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WOUND CARE PRODUCTS 
Table No 3A Shows Wound Care Products 
A wide variety of wound care products are available; a brief listing 
of dressings and topical agents is presented in Table No 3A and 3B 
Category Indications  
Dressings 
Gauze Pad 
Sterile Gauze 
Sterile Cotton 
Low to heavily draining 
wounds or surgical wounds 
Wet to dry debridement 
Undefined 
Transparent Films 
Polyurethane film with  
drainage adhesive layer,  
semi permeable 
Dry to minimally draining 
wounds 
Promote tissue hydration 
Infection 
Significant change 
Over prominence or 
friction 
Hydrogels 
Gel, sheet, gauze  
(95% water or glycerin) 
Dry to minimally draining 
wounds 
Moderate or heavy 
drainage 
Foam 
Polyurethane foam  
(open cell, absorbent) 
Moderate, large exudate 
Clean wound surface 
Super absorbent and 
conformable to topography 
Dry wounds 
Hydrocolloids 
Water with adhesion, 
(carboxymethylcellulose 
pectin, gelatin)  
impermeable to oxygen 
Low to moderate drainage 
Prevents tissue hydration 
Heavy drainage 
Sinus tract 
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Calcium alginates 
Fiber pad derived from 
seaweed (may be combined 
with silver or collagen) 
Heavy exudative wounds 
Minimal drainage or 
dry wounds 
Collagen dressings 
Particles or composite pads 
with collagen components 
(derived from bovine 
collagen) 
Low to heavily raining 
wounds 
Dry wounds 
Antimicrobial dressings 
Contain silver, iodine in 
various forms preparations 
(eg, cadoxemer iodine) 
Infected or clean wounds to 
prevent infection 
Allergies to 
components 
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Table No 3B Shows Wound Care Products 
Category Indications  
Topical Therapies/Agents 
Amorphous Hydrogels 
Skin Cleansers 
Isotonic solutions for 
irrigation, hydrating 
dressings 
Clean or infected 
wounds 
Undefined 
Detergents/Antiseptics 
Povidone-Iodine, 
Chlorhexidine 
Chloroxylenol 
Hypochlorite 
Benzethonium Chloride 
Contaminated or 
infected wounds 
Healthy granulating 
wounds 
Topical Antibiotics 
Bacitracin, neomycin 
Mupirocin, polymyxin B 
Silver sulfadiazine 
Mafenide (creams, 
ointments) 
Contaminated or 
infected wounds 
Healthy granulating 
wounds 
Enzymes 
Collagenase 
Papain-urea 
Necrotic tissue 
Escharotic wounds 
Healthy or infected 
wounds 
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ADVANCED WOUND CARE MODALITIES 
“Wound bed preparation offers clinicians a comprehensive 
approach to removing barriers to healing and stimulating the healing 
process so that the benefits of advanced wound care can be maximized. 
Advanced care may sometimes be the only means of rapidly and 
effectively attaining wound closure. The advent of therapeutic growth 
factors, gene therapy, tissue-engineered constructs, stem cell therapy, and 
other drugs and devices that act through cellular and molecular-based 
mechanisms is enabling the modern surgeon and wound-care provider to 
actively promote wound angiogenesis to accelerate healing”. 
I) GROWTH FACTOR THEORY 
“Chronic ulcers have demonstrated benefit from autologous platelet 
releasatesor genetic engineered products such as recombinant DNA 
platelet derived growth factor . This agent has been shown to stimulate 
chemotaxis and mitogenesis of neutrophils, fibroblasts and monocytes 
and other monocytes that form the cellular basis of wound healing. In one 
pivotal randomized placebo-controlled blinded trial involving patient with 
full thickness diabetic foot ulcers, recombinant human platelet-derived 
growth factor (Becaplermin) demonstrated a 43% increase in completed 
closures vs placebo gel (50% vs 35%). Other growth factors, including 
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vascular endothelial growth factor (VEGF), fibroblast growth factor 
(FGF), and keratinocyte growth factor (KGF), have been under study”. 
“Autologous platelet-rich plasma treatments utilize the patient’s 
own blood to create a gel that is applied to the wound. Activation of the 
plasma after centrifugation stimulates the release of multiple growth 
factors from the platelet’s alpha granules and the conversion of the 
plasma fibrinogen to a fibrin matrix scaffold. Both actions may assist with 
the new tissue formation. A large retrospective study reviewing this 
treatment protocol in commercial wound healing centers suggested a 
benefit in healing of larger and more severe neuropathic ulcer”. 
II) ADJUNCTIVE MODALITIES 
i) “Regenerative tissue matrix is a new therapy used in diabetic foot 
ulcers, although it has undergone any random clinical trials to date. 
This allograft skin is minimally processed to remove the epidermal 
and dermal cells while preserving the bioactive components and 
structure of dermis. This results in a framework that supports 
cellular repopulation and visualization”. 
ii) “Hyperbaric Oxygen therapy (HBO) has shown promise in the 
treatment of diabetic foot wounds with hypoxia sever enough to 
interfere with the healing. However, most of the HB studies were 
hampered by methodological errors that preclude any definite role 
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for this modality in the routine treatment of diabetic foot ulcers. 
Nevertheless, in 2003, Medicare and Medicaid coverage for HBO 
extended to ulcers classified as Wagner grade 3 or higher that failed 
standard wound care therapy. Clearly, a large multicenter 
randomized clinical trial is needed to properly test the efficacy of 
this expensive modality” 
iii) “Several new ultrasound devices are being used toboth debride 
the wound and provide ultrasonic theory. The MIST therapy system 
(Celleration, Eden Prairie, MN) is an ultrasonic device approved by 
the Food and Drug Administration (FDA) for wound debridement 
and cleansing. MIST Therapy uses a fine saline spray that allows 
ultrasound to be administered directly to the wound bed without 
contact to the affected tissue, thus minimizing the potential trauma 
to delicate capillary buds and emerging islands of epithelium”.  
iv) “Negative pressure wound therapy (NPWT)has become a 
common adjunctive treatment modality for diabetic foot 
ulcerations. Use of a vacuum-assisted closure device (V.A.C., KCI, 
San Antonio, TX) promotes wound healing through the application 
of topical, sub atmospheric, or negative pressure to the wound base. 
This therapy removes edema and chronic exudates, reduces 
bacterial colonization, enhances formation of new blood vessels, 
increases cellular proliferation, and improves wound oxygenation 
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as the result of applied mechanical force. These actions are 
synergistic. Numerous applications of this modality have proven 
successful, including use over exposed bone, tendons, and 
hardware to generate granulation tissue. It is also frequently used to 
facilitate adherence of split thickness skin grafts, rotational flaps, or 
tissue substitutes to a wound bed. A recent clinical trial of the 
V.A.C. device for the treatment of open amputation wounds in the 
diabetic foot showed significantly faster healing and development 
of granulation tissue with NPWT compared with standard moist 
wound care”. 
v) “The rationale for using electrical simulation in wound healing 
sterns from the fact that the human body has an endogenous 
bioelectric system that enhances healing of bone fractures and soft 
tissue wounds. Laboratory and clinical studies provide an 
abundance of support for the use of electrical simulation in wound 
care. In a randomized, controlled study evaluating wound healing 
using electrical simulation in neuropathic ulcers, significant 
differences in healed ulcer areas and number of healed ulcers at 12 
weeks were found in the group receiving electrical stimulation 
compared with the control group”. 
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III) PRESSURE RELIEF/OFF-LOADING 
“The reduction of pressure especially to the diabetic foot ulcer is 
essential to treatment. Proper off-loading and pressure reduction prevents 
further trauma and promotes healing. This is particularly important in the 
diabetic with decreased or absent sensation in the lower extremities. 
Furthermore, recent studies provide evidence that minor trauma  
(eg, repetitive stress, shoe pressure) plays a major role in the casual 
pathway to ulceration”. 
“The choice of off-loading modality should be determined by the 
patient’s physical characteristics and ability to comply with the treatment 
as well as by the location and severity of the ulcer. A study published in 
2001 noted that the use of Total Contact Cast (TCC) heals better”. 
“The shoe causing ulcer should be removed till ulcer heals and to be 
replaced by new modified footwear”. 
IDEAL DRESSING 
“Goal of wound dressing is to provide warm moist environments 
that are free of external contamination. The ideal dressing for granulation 
tissue should be one that is soft, absorbent, non-adherent and non-allergic. 
Although the ideal dressing does not exist, there are groups of dressing 
providing a comprehensive cure”. 
      
 
RECOMBINANT EPIDERMAL GROWTH FACTOR DRESSING
“REGEN D 150 
Human Epidermal Growth factor 
growth resulting in faster wound healing
EPIDERMAL GROWTH FACTOR
“EGFs are produced by several different cell types and act on 
epithelial cells, stimulating their migration and cell division. EGF has 
been shown to enhance wound healing. Besides growth factor , other 
extra cellular signals including disruption of cell
35 
contains indigenously developed recombinant 
(EGF) that helps in stimulation of cell 
”. 
 
-cell or cell matrix 
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contacts and the provisional matrix, might contribute to the initiation of 
migration reepithelialization and activation of gene expression”. 
“EGF is a polypeptide involved in the maturation of epithelial. It 
binds to the EGF receptor (EGFR) which is also a receptor for cytokines 
such as TGF-alpha. In normal adult epidermis, EGFR is predominantly 
expressed in basal keratinocytes and signalling events elicited by it are 
known to affect their proliferation, differentiation and migration. In 
healing skin wounds, EGFR expression is up regulated in migrating and 
proliferating keratinocytes adjacent to the wound. Clinical studies of the 
influence of treatment of skin wounds with soluble EGF have revealed a 
stimulatory function of this growth factor in wound healing. An early 
event after treatment of cultured epithelial cells with EGF is remodelling 
of the actin cytoskeleton, which can lead to retraction of cells from the 
substrate and rounding. EGF also stimulates centrifugal outwards 
migration of keratinocytes within colonies”. 
“Resident cell types, which comprise the skin, such as the keratinocytes 
and fibroblasts, have proved growth responsiveness to EGF in tissue 
culture. The necessary receptor, EGFR for binding of EGF and TGF-
alpha is present in normal skin. Thus, wounded skin could respond to 
either endogenous or exogenous application of EGF. Published studies of 
other proliferative conditions indicate that EGF, TGF-alpha or the EGFR 
      
37 
 
is greatly increased in skin. Several in vitro and in vivo reports suggest 
that a proliferative process such as wound healing should be responsive to 
exogenous manipulation using EGF”. 
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MATERIALS AND METHODS 
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MATERIALS AND METHODS 
Study design   :  Prospective randomised control trial 
Source of data   :  Patients admitted to various surgical units  
     at the Institute of General Surgery,  
     Madras Medical College, Chennai  were  
     the source of sample 
Study period   :  March 2016 – September  2016 
Sample size    :  Totally 104  patients were enrolled in the study 
Control group   :  52 patients 
Study group   :  52 patients 
 
Wherein 1 patient in the study group and 1 patient in the control 
group lost follow up. 1 patient in the control group had to undergo 
amputation and 1 patient in the study group had limb ischemia. 
Hence the study was concluded with 100 patients , 25 in each 
group.  
 
Inclusion Criteria : 
a) All  patients above 18 yrs of age 
b) Traumatic, infectious, venous or pressure ulcers 
c) Grade I or II ulcers defined by Wagner’s classification on any part 
of the body 
d) Ulcers with adequate perfusion 
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e) Patients presenting with necrotising fasciitis or abscesses or 
bedsores were enrolled in the study after initial debridement of the 
affected area 
Exclusion criteria : 
a) Below 18 yrs 
b) Pregnant women 
c) All ischemic ulcers with Doppler proven occlusion of vessels 
d) Radiologically proven osteomyelitis 
e) All malignant ulcers 
f) Electrical or radiation wounds 
g) Burns wounds 
Methods :  
• Patients with above mentioned criteria admitted to our hospital 
were included in the study. 
• Proforma was attached to their case records and filled up with 
details necessary before the start of the study. 
• After a thorough clinical examination, they were investigated. 
Besides the routine haematological and biochemical  parameters, 
USG Doppler for vascular  evaluation and x-ray of the affected part 
were done to look for any evidence of osteomyelitis and were 
excluded  from the study 
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• Good glycemic control was ensured by diabetic diet and adjusting 
the dose of insulin with periodic blood sugar measurements. 
• After initial thorough debridement the dressings were started and 
subsequent debridements were done as and when required 
• The patients were randomised into two groups of 27 each. 
• The size of the ulcer was measured by cutting a gauze piece to the 
size of the wound and calculating the surface area of the ulcer 
approximately. 
• Wound swab was taken for culture and sensitivity in all cases and 
antibiotics were given wherever necessary as per the sensitivity 
pattern 
• The study group were dressed with recombinant epidermal growth 
factor gel and the other group were dressed with routine normal 
saline dressing. 
• All the wounds were measured once in two weeks and the value 
recorded in the proforma. 
• The final measurement was done at the end of 6 weeks and an 
endpoint wound swab culture done. 
• The difference between the initial and final measurement was taken 
into account for analysis of results. 
 
      
42 
 
 
Table 4 WAGNER’S CLASSIFICATION  
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PICTURE SHOWING WOUND HEALING IN A PATIENT UNDER 
CONTROL GROUP 
 
2 WEEKS 
 
 
4 WEEKS 
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PICTURE SHOWING WOUND HEALING IN A PATIENT UNDER 
STUDY GROUP 
            
  
2 WEEKS 
6 WEEKS 
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PICTURE SHOWING WOUND HEALING IN A PATIENT UNDER 
STUDY GROUP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ON ADMISSION 
6 WEEKS 
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PICTURE SHOWING WOUND HEALING IN A PATIENT UNDER 
STUDY GROUP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ON ADMISSION 
6 WEEKS 
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PICTURE SHOWING WOUND HEALING IN A PATIENT UNDER 
STUDY GROUP 
 
ON ADMISSION 
 
 
 
 
 
 
6 WEEKS 
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PICTURE SHOWING WOUND HEALING IN A PATIENT UNDER 
STUDY GROUP 
 
 
2 WEEKS 
 
4 WEEKS 
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PICTURE SHOWING SMALLEST ULCER SIZE 
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PICTURE SHOWING WOUND HEALING IN A PATIENT UNDER 
CONTROL GROUP 
 
 
 
AT 6 WEEKS 
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PICTURE SHOWING WOUND HEALING IN A PATIENT UNDER 
CONTROL GROUP 
 
 
 
 
 
 
 
 
2 WEEKS 
6 WEEKS 
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PICTURE SHOWING WOUND HEALING IN A PATIENT UNDER 
STUDY GROUP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
ON ADMISSION 
2 WEEKS 
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PICTURE SHOWING WOUND HEALING IN A PATIENT UNDER 
STUDY GROUP 
 
TRAUMATIC FOREARM ULCER 
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PICTURE SHOWING WOUND HEALING IN A PATIENT UNDER 
STUDY GROUP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ON ADMISSION 
4 WEEKS 
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PICTURE SHOWING WOUND HEALING IN A PATIENT UNDER 
STUDY GROUP 
 
SCROTAL ULCER 
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PICTURE SHOWING WOUND HEALING IN A PATIENT UNDER 
STUDY GROUP 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
2 WEEKS 
6 WEEKS 
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RESULTS 
Sample size : Total of  104 patients were recruited to the studyTwo 
patients one from each group lost follow up and were excluded. 
One patient in control group had to undergo amputation as he 
developed uncontrolled sepsis. 
One patient in study group had doppler confirmed ischemia and 
was excluded. 
The study ended with 100 patients with 
Study group having 50 patients and 
Control group having 50 patients. 
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SAMPLE SIZE DISTRIBUTION 
Gender distribution : 
 
Category Female Male Total 
EGF 10 40 50 
NS 11 39 50 
Total 21 79 100 
 
The gender distribution in both groups were predominantly males 
and the percentage was similar in both groups. 
AGE  WISE  DISTRIBUTION
 
      
 
Category < 40 years
EGF 
NS 
Total 
 
Most of the patients 
was similar in both groups.
The youngest patient was 28 yrs old and the eldest
Mean age was 51.1
 
< 40 years
40 to 50 years
50 to 60 years
> 60 years
60 
 
 
40 to 50 
years 
50 to 60 
years 
7 21 12 
4 24 16 
11 45 28 
in our study were between 40 and 50 yrs which 
 
 years overall,( SD ) 
 
14%
42%
24%
20%
8%
32%
12%
Age wise Distribution
NS EGF
 
> 60 years Total 
10 50 
6 50 
16 100 
 was 71 Years. 
48%
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ETIOLOGY OF ULCERS 
 
Category Infective Traumatic Venous Total 
EGF 45 4 1 50 
NS 46 2 2 50 
Total 91 6 3 100 
 
The most common etiology was infective and found to be similar in 
both groups. The second most common cause was traumatic followed by 
venous ulcers. 
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SITE OF ULCERS 
 
 
Category Leg Thigh Foot Forearm Total 
EGF 33 7 6 4 50 
NS 39 5 1 5 50 
Total 72 12 7 9 100 
 
The most common site of ulcers was the leg which was similar in 
both groups. The thigh and the foot were the next common. Unusual sites 
such as forearm, scrotum and back were also present and were equally 
distributed in both groups.  
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DIABETES MELLITUS 
 
Diabetes Yes No Total 
EGF 13 37 50 
NS 12 38 50 
Total 25 75 100 
 
As we know that DM is the most common etiology of infective 
ulcers its distribution was plotted and found to be equal in both groups 
with  75% of the total studied patients being diabetics. 
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OTHER COMORBIDITIES 
 
Category HTN CAD SLE CKD 
EGF 5 1 1 10 
NS 6 0 0 8 
Total 10 1 1 18 
 
Other  than DM, hypertension, CKD, and CAD were found in both 
the groups in equal distribution. Identifying these illnesses was important 
,as the treatment for these conditions were started and continued along 
with the ulcer management to avoid bias.  
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ULCER SIZE 
The surface area of the ulcer as measured and recorded at the end 
of  2nd  week, 4th week and 6th week were taken into accountand their 
mean obtained and plotted as below. 
 
Average Size 
of Ulcer 
Initial End of 2 weeks 
End of 4 
weeks 
End of 6 
weeks 
EGF 187 166 138 109 
NS 165 158 150 137 
 
The minimum size of ulcer was 86 sq.cm 
The maximum size was 284 sq.cm 
Mean size being 186.2 sq.cm in study group and 165.06 sq.cm in the 
control group 
      
66 
 
REDUCTION IN ULCER SIZE PER WEEK 
 
Category Overall Reduction in % 
EGF 7.2% 
NS 2.9% 
 
The healing rate of study and control groups were analysed by 
calculating the percentage reduction in size per week in each group. This 
value was significantly high in the study group at a rate of 7.2% against 
2.9% in control group. P value <0.001. 
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REDUCTION IN SIZE AT 6 WEEKS 
 
 
>50% Reduction No Yes Total 
EGF 40 10 50 
NS 50 0 50 
Total 90 10 100 
 
Ulcers showing >50% reduction in size at the end of 6 weeks were 
recorded and analysed and was found to be significantly present in 20% 
of the study group population. Whereas none of the control group patients 
showed a 50% reduction in size. P value was <0.001 
 
      
68 
 
REDUCTION OF SIZE IN DIABETICS 
 
Average Size of 
Ulcer 
Initial 
End of 2 
weeks 
End of 4 
weeks 
End of  
6 weeks 
EGF 205 182 151 122 
NS 174 166 159 146 
 
As the entire group comprised predominantly of patients suffering 
from Diabetes Mellitus the variation that the studied drug could produce 
on diabetic population were analysed. The size of the ulcer reduced in the 
study group significantly from a mean of 205 sqcm to 122 sq.cm 
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REDUCTION  % IN DIABETICS 
 
 
Category Average of Overall Reduction in % 
EGF 6.8% 
NS 2.7% 
 
There was a 6.8% reduction in size per week in the diabetic patients 
of the study group compared to 2.7% reduction per week in control group. 
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REPEAT DEBRIDEMENT 
 
Category No Yes Total 
EGF 50 0 50 
NS 36 14 50 
Total 86 14 100 
 
None of the patients in study group required repeat debridement. 
While 28% of the control group patients required debridement during the 
course of the study. Surgical debridement was done when and where 
necessary. 
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WOUND SWAB AT THE END OF 6 WEEKS 
 
 
Category Minus Plus Total 
EGF 45 5 50 
NS 6 44 50 
Total 51 49 100 
  
The study group surprisingly showed a significant  absence of 
micro organism  overgrowth when studied at the end. 90% of the study 
group had a negative culture compared to the 88% of the control group 
showing positivity. The p value was <0.001 
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DISCUSSION 
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DISCUSSION 
Ulcers are being treated with different  modalities on a day to day 
basis at various parts of our country. India being the diabetic capital of the 
world, have significant number of patients with ulcers that are non-
healing adding to the morbidity. The study included all such patients with 
large or non-healing ulcers. 
Age and Sex Distribution:  
The mean age in our study was 51.01years in par with the mean age 
of 51.2 years in the control group. This correlates with other similar 
studies that have reported a mean age of 52 years. When the ulcers are 
large or occurring in diabetics the amputation rate is usually higher. 
Recurrence of ulcers at a same or different  site can also occur especially 
in diabetics.  
In our study the ulcers were seen most commonly in males 
compared to females. The increased incidence in males may be because 
they are exposed to external environment more when compared to 
females  which is prevalant in the rural part of our  country . Further , 
traumatic ulcers are more common in males owing to the increasing rate 
of road traffic accidents. 
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Etiology of ulcers 
The most common etiology of ulcers being diabetes mellitus. 
Which again can be due to one among the following risk factors such as 
peripheral neuropathy, micro or macro angiopathy, limited joint mobility, 
foot deformities, abnormal foot pressures, minor trauma, impaired visual 
acuity. The second most common etiology were traumatic either major or 
minor which get secondary  infection. Nonhealing wounds can become 
stuck in the inflammatory phase of healing, increasing cytokine response 
with subsequent elevated protease levels and impaired growth factor 
activity. The study group had major number of diabetics and so the most 
common etiology was infection followed by trauma. Venous ulcers were 
only a minor percentage in both groups. 
Systemic Disease 
Other than hyperglycemia comorbidities such as hypertension, 
coronary artery disease, chronic kidney disease were present in the 
sample. Systemic diseases such as cerebro vascular accidents, angina, 
valvular heart diseases, hypercholesterolemia though prevalent in our 
country , were not present in the studied group. Because diabetes itself 
being a multi organ disease all other comorbidities affecting wound 
healing had to be assessed and managed by a multidisciplinary team for 
optimal outcomes in ulcer management. That is why we have treated all 
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our cases with comorbidities with systematic consultation obtained from 
vascular surgeons, cardiologists, nephrologists, and general physicians. 
One of our study group patient was sufferring from SLE and the condition 
was treated concordantly with our ulcer management with periodic review 
by rheumatologists. 
Reduction in ulcer size 
In our study there was a significant reduction in size of ulcer in the 
study group as compared to the control group. Regen D dressing was 
faster and better in healing ulcers. The mean ulcer size reduced from 187 
sq.cm to 109 sq.cm in the regen D group. Whereas the normal saline 
dressing showed a marginal reduction from 165 sq.cm to 137 sq.cm. 
The rate of reduction in size was 7.2% per week in the study group 
which was much higher than the 2.9% reduction in size in the control 
group in a week. 
The diabetic patients showed an approximately equal reduction rate 
of 6.8% per week which was again higher than the control group value of 
2.7%. Henceforth, diabetes is not found to alter or reduce the efficacy or 
recombinant EGF in wound healing. 
  
      
76 
 
At the end of 6 weeks 20% of patients in the study group showed 
more than 50% reduction in the size of the ulcer which was a dramatic 
response when compared to none of the control group patients showing a 
similar reduction in size.  
Repeat debridement 
The study group did not require repeat debridement at all as the 
healthy granulation tissue once appeared in the beginning of second week 
was floridly covering the entire wound and did not require slough 
excision until the wound bed was ready for skin grafting. Whereas 
wounds dressed with normal saline required repeat debridement and 
slough excision in 28% of the sample size. 
Wound swab cultures 
The ulcers were periodically swabbed for micro organism growth 
from the initial debridement till the end of study. According to the 
sensitivity reports antibiotics were prescribed and administered. The study 
group dressed with regen D showed a gradual decline in the growth of 
micro organisms in wound swabs. This may be owed to the increased 
amount of healthy granulation tissue formation providing local immunity 
which itself acts as a barrier to microorganism growth. Mixed cultures 
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were present in the patients showing positivity. Staphylococcus, 
klebsialla, and pseudomonas were the most common organism grown. 
Healing 
Overall, the use of recombinant epidermal growth factor is found to 
improve the rate of ulcer healing be it in diabetics or others. There were 
no reported side effects of this gel in the study group. And no such side 
effects have been reported in the literature.  
Recombinant human epidermal growth factor stimulates the 
proliferation and migration of epithelial cells in human culture systems. 
rhEGF has been shown to enhance the rate of healing thereby quickly 
providing a healthy surface over the ulcer . The ulcer healing can further 
be quickened by skin grafts placed over these healthy vascular sterile 
ulcers.  
The morbidity and prolonged hospital stay required to treat large 
ulcers can thus be reduced by the use of regen D 
It is clear that dressings are the only element in the holistic 
management of patients with ulcers. In addition to dressing selection, 
emphasis must be made on good glycemic control,pressure reduction, 
appropriate antibiotic therapy and skilled debridement. 
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CONCLUSION 
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CONCLUSION 
The results of this study suggest that, within the clinical setting, as 
part of a comprehensive wound management program 
• Diabetes is a more common etiology for large and non-healing 
ulcers and occurs more commonly over legs 
• The Recombinant Human Epidermal Growth Factor is efficient in 
reducing the size of large ulcers to a significant extent. 
• The efficacy of rhEGF does not seem to be lowered in diabetics or 
other systemic illness. 
• The rhEGF is found to significantly lower the infection rate of 
ulcers. 
• rhEGF has an excellent safety profile and easy to use by patients or 
by care givers outside the clinical setting. 
• The use of rhEGF , as indeed of every new therapeutic modality, 
should not be practised alone, but be incorporated in a holistic 
strategic approach. 
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